August 6, 2020 5:44pm

We’re going through quarterly financial results <notice I didn’t say – “earnings” season, my fear is that the Q2 LPS <loss-per-share> aren't going to look much better than the Q1 numbers with a serious future question of Q3 numbers

Pre-open indication results: 8 HITs and 2 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't; I put into context what is relevant for investors

Subscription is coming, my gift to you however, I've kept RMi subscription FREE during these COVID-19 and volatile times!


The Dow closed UP +185.46 points (+0.68%), the S&P closed UP +21.39 points (+0.64%) while the NASDAQ closed UP +109.67 points (+1%)

 

Pre-open indication results: 7 HITS < Editas Medicine (EDIT +$4.35), Mesoblast (MESO -$0.23), Caladrius Biosciences (CLBS -$0.27), Global Blood Therapeutics (GBT -$3.86), bluebird bio (BLUE +$1.78), Intellia Therapeutics (NTLA +$0.34), Precigen (PGEN -$0.13)> and 3 MISS < AxoGen (AXGN -$0.27), Biostage (BSTG +$0.32),  Ionis Pharmaceuticals (IONS -$0.97)>

 

Henry’omics:

Indexes rose on Thursday, led by tech shares, as traders kept an eye on Washington for clues on a new coronavirus stimulus package and pored over better-than-expected unemployment data.

  • The Labor Department said initial jobless claims for the week ending Aug. 1 totaled 1.186 million. That’s well below an estimate of 1.423 million and the lowest claims level since the pandemic began.

This a.m. I stated in this a.m.’s newsletter - RegMed Investors’ (RMi) pre-open: RegMed Investors’ (RMi) pre-open: a “Devil’s Advocate” … In building probable explanations of yesterday’s versus today’s actions … https://www.regmedinvestors.com/articles/11489

Also, this a.m.’s Biostage (BSTG) Chronicles also offered a warning especially their “art of deceptions” re past or current liabilities and WHY a such cash poor and thinly capitalized company GIFTS $1 million to a hospital, but… a Connecticut Childrens’ CEO is one BSTG’s board of directors?

  • Funny, how just before the close BSTG jumps to MAINTAIN the share price – WHO is the usual BUYER of the U.S. NASDAQ OTC listing shares while the last private placement pricing of millions of shares priced at $3.70. SEC take notice … 6 shares traded to 1406 in no-time-flat!

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened negative at 11/21 and 3 flats, stayed negative at the mid-day at 11/22 and 2 flats, closing negative at 11/23 and 1 flat;
  • Wednesday opened positive at 17/14 and 4 flats, stayed positive at the mid-day at 19/15 and 1 flat, closing positive at 19/15and 1 flat;
  • Tuesday opened negative at 8/25 and 2 flats, stayed negative at the mid-day at 13/21 and 1 flat, closing negative at 13/20 and 2 flats;
  • Monday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 25/3 and 2 flats, closing positive at 31/1 and 3 flats;

 

Key metrics:

  • Sector volume was LOW with 6 of the 11-upside having higher than the 3-month average volume and the 4 of 23-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 11-upside were +0.02% (QURE) to +14.68% (BSTG) while the 23-downside ranged -0.38% (ATHX) to -10.38% (CLBS); 

 

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Global Blood Therapeutics (GBT), ReNeuron (RENE.L), CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) to name 5 of the 11 declining of the 35 covered

Jumping with share pricing momentum:

  • Editas Medicine (EDIT), bluebird bio (BLUE), Ultragenyx (RARE), Fate Therapeutics (FATE), Intellia Therapeutics NTLA) to name 5 of the 11 trading up of 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -0.38% and XBI also closed down -0.51%
  • Wednesday, the IBB closed down -0.29% and XBI also closed up +0.72%
  • Tuesday, the IBB closed down -0.64% and XBI also closed down -0.31%
  • Monday, the IBB closed up +3.13% and XBI also closed up +4.20%

 

Thursday’s (11 of 11) incliners:

  • Editas Medicine (EDIT +$4.35 after Wednesday’s +$0.61, Tuesday’s +$0.31 and Monday’s +$2.21);
  • bluebird bio (BLUE +$1.78 after Wednesday’s -$0.38, Tuesday’s -$0.34 and Monday’s +$2.08);
  • Ultragenyx (RARE +$1.10 after Wednesday’s -$0.71, Tuesday’s +$0.63 and Monday’s +$5.38);
  • Fate Therapeutics (FATE +$0.58);
  • Intellia Therapeutics (NTLA +$0.34);
  • Biostage (BSTG +$0.32 after Wednesday’s +$0.06, Tuesday’s -$0.01 and Monday’s -$0.37);
  • Sangamo Therapeutics (SGMO +$0.22);
  • Voyager Therapeutics (VYGR +$0.18 after Wednesday’s +$0.46 and Tuesday’s -$0.98);
  • Regenxbio (RGNX +$0.11 after Wednesday’s +$0.45 and Tuesday’s -$0.59);
  • MiMedx (OTC Pink sheets: MDXG +$0.10);
  • uniQure NV (QURE +$0.01 after Wednesday’s -$0.42);

Thursday’s (10 of 23) decliners:

  • Alnylam Pharmaceuticals (ALNY -$6.32 after Wednesday’s -$2.32, Tuesday’s +$0.46 and Monday’s +$6.54);
  • Global Blood Therapeutics (GBT -$3.86 after Wednesday’s -$0.86, Tuesday’s -$1.72 and Monday’s +$3.00);
  • ReNeuron (RENE.L -$3.50 after Wednesday’s -$2.50);
  • CRISPR Therapeutics (CRSP -$1.57);
  • Ionis Pharmaceuticals (IONS -$0.97 after Wednesday’s -$2.32);
  • Brainstorm Cell Therapeutics (BCLI -$0.96 after Wednesday’s -$0.28 and Tuesday’s -$0.69);
  • Cellectis SA (CLLS -$0.87 after Wednesday’s +$0.52);
  • Pluristem (PSTI -$0.79);
  • Vericel (VCEL -$0.75 after Wednesday’s -$0.90 and Tuesday’s -$0.37);
  • Sage Therapeutics (SAGE -$0.70 after Wednesday’s +$0.91 and Tuesday’s +$3.37);

Closing flat: 1 – Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: comparisons

  • Thursday’s percentage (%) of the 11-upside were +0.02% (QURE) to +14.68% (BSTG) while the 23-downside ranged -0.38% (ATHX) to -10.38% (CLBS); 
  • Wednesday’s percentage (%) of the 19-upside were +0.31% (NTLA) to +6.12% (CLBS) while the 15-downside ranged -0.06% (CRSP) to -5.35% (VCEL); 
  • Tuesday’s percentage (%) of the 13-upside were +0.08% (IONS) to +7.52% (MESO) while the 20-downside ranged -0.10% (BLFS) to -8.90% (ADRO); 
  • Monday’s percentage (%) of the 31-upside were +1.33% (AGTC) to +8.24% (CRSP) while the 1-downside was -14.80% (BSTG); 

 

Sentiment and a few daily indicators:

We are still waiting for clues on a new coronavirus stimulus package …

  • Thursday 4.85 cases
  • Wednesday 4.7 cases
  • Tuesday 4.71 cases
  • Monday 4.66 cases,

Thursday’s death rate totaled 159,433 after Wednesday’s 157,186 after Tuesday’s 155,478 and Monday’s 154,860 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Thursday: 6 out of the 11-upside had higher than the 3-month average volume;
  • Wednesday: 2 out of the 19-upside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 13-upside had higher than the 3-month average volume;
  • Monday: 8 out of the 31-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.34 points or -1.48% at 22.65
  • Wednesday was down -0.77 points or -3.24% at 22.99
  • Tuesday was down -0.52 points or -2.14% at 23.76
  • Monday was down -0.18 points or -0.74% at 24.28

Downside volume:

  • Thursday: 4 out of the 23-downside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 15-downside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 20-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

August, the second month of Q3 …

Thursday closed negative with 11 advancers, 23 decline and 1 flat

Wednesday closed positive with 19 advancers, 15 decline and 1 flat

Tuesday closed negative with 13 advancers, 20 decline and 2 flats

Monday (8/3) closed positive with 31 advancers, 1 decline and 3 flats

 

The Bottom line:  Ask yourself, do you know why you own certain equity? What’s been communicated re a company’s status at any given time to shareholders other than quarterly reports or a once-upon-a-time press release!

The RegMed sector suffers the tourist routine bad, good and no news or information from “where” gets sold into.  Lately it’s the “rules” of the algorithms, dark pools and ETFs but … disruption can come in many forms!

In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned. 

It’s important for investors to identify and determine which of MY posted indications are actually performance based.

Venimus nos emit et vendidit nos rursus” – “We have bought and sold again". That's why today's a BAD day for all who own cell and gene therapy equities.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.